In Episode 5, Drs. Aly-Khan Lalani and Christopher Wallis discuss biochemical recurrence in prostate cancer, including what they’re seeing in the field right now in terms of treatment options, what physicians should know moving forward and multi-D care for patients. The doctors also provide an overview of the recent EMBARK trial, noting efficacy outcomes and key learnings. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com This podcast has been made possible through financial support by Bristol Myers Squibb, Merck, and TerSera. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of hospital corporations and are not intended to be personal medical advice.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related